IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Gu, Fang Ming ^a   Li, Quan Lin ^a   Gao, Qiang ^a   Jiang, Jia Hao ^a   Zhu, Kai ^a   Huang, Xiao Yong ^a   Pan, Jin Feng ^a   Yan, Jun ^a   Hu, Jin Hui ^b   Wang, Zheng ^a   Dai, Zhi ^a   Fan, Jia ^a   Zhou, Jian ^a  

^a FUDAN UNIVERSITY   (China)

^b Gongli Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER SURGERY; CARCINOMA CELL; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHEMISTRY; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DRUG EFFECT; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

MUS MUSCULUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83455162844     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-150     Document Type: Article

References (35)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010, 28:4045-4051. 10.1200/JCO.2010.27.9992, 20644090.
3. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898. 10.1056/NEJMra0707449, 19710487.
4. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149. 10.1182/blood-2009-03-208249, 2723011, 19470694.
5. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182. 10.1002/pros.10238, 12772186.
6. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008, 374:533-537. 10.1016/j.bbrc.2008.07.060, 18655770.
7. Bronte V. Th17 and cancer: friends or foes?. Blood 2008, 112:214.
8. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009, 183:4169-4175. 10.4049/jimmunol.0901017, 19767566.
9. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627. 10.1182/blood-2002-05-1461, 12411307.
10. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, Banchereau J, Fridman WH, Wijdenes J, Lebecque S, Sautes-Fridman C. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999, 59:3698-3704.
11. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99:2114-2121. 10.1182/blood.V99.6.2114, 11877287.
12. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008, 14:3254-3261. 10.1158/1078-0432.CCR-07-5164, 3082357, 18519750.
13. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011, 71:661-665. 10.1158/0008-5472.CAN-10-1259, 21148486.
14. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009, 50:980-989. 10.1016/j.jhep.2008.12.033, 19329213.
15. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464. 10.1084/jem.20090207, 2715087, 19564351.
16. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567. 10.1038/nri2586, 2821718, 19575028.
17. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
18. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-423. 10.1038/nm843, 12640447.
19. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15:971-979. 10.1158/1078-0432.CCR-08-1608, 19188168.
20. Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding ZB, Devbhandari RP, Huang XY, Qiu SJ, Shi YH, Dai Z, Yang XR, Yang GH, Fan J. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 2010, 52:183-196.
21. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, Ren YB, Su B, Cao GW, Yang Y, Yan YQ, Shen F, Wu MC, Feng GS, Wang HY. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011, 53:181-192. 10.1002/hep.24015, 21254169.
22. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and Liver Cancer. Annals of the New York Academy of Sciences 2009, 1155:206-221. 10.1111/j.1749-6632.2009.03704.x, 19250206.
23. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
24. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
25. Sparna T, Retey J, Schmich K, Albrecht U, Naumann K, Gretz N, Fischer HP, Bode JG, Merfort I. Genome-wide comparison between IL-17 and combined TNF-alpha/IL-17 induced genes in primary murine hepatocytes. BMC Genomics 2010, 11:226. 10.1186/1471-2164-11-226, 2858152, 20374638.
26. Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 2009, 32:109-117. 10.1097/CJI.0b013e31819302da, 19238009.
27. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005, 175:6177-6189.
28. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2011, 129:311-321.
29. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, Nishihara M, Iwakura Y, Hirano T. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636. 10.1016/j.immuni.2008.07.018, 18848474.
30. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010, 70:10112-10120. 10.1158/0008-5472.CAN-10-0775, 3059780, 21159633.
31. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51. 10.1038/nri1995, 17186030.
32. Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007, 179:6504-6513.
33. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004, 6:R120-128. 10.1186/ar1038, 400429, 15059275.
34. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, Rousseau S. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010, 184:4531-4537. 10.4049/jimmunol.0903162, 20228195.
35. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2010, 54:497-505.